{
  "outcomes_metadata": {
    "timestamp": "2025-10-01T15:22:56.298139",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 54,
    "source_countries": [
      "DE",
      "DK",
      "EN",
      "EU",
      "FR",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "overall survival",
        "prolonged survival",
        "event-free survival",
        "eventless survival",
        "progression-free survival (PFS)",
        "progression-free survival (blinded independent central review)",
        "progression-free survival (RECIST v1.1)",
        "progression-free survival (PFS; RECIST v1.1)",
        "progression-free survival (independent, blinded review panel; RECIST 1.1)",
        "progression-free survival (centrally-assessed)",
        "progression-free survival (investigator-assessed)",
        "progression-free survival",
        "progression after next line of therapy (PFS2)"
      ],
      "response_measures": [
        "objective response rate (ORR)",
        "objective response rate (RECIST 1.1, blinded independent central review)",
        "objective response rate (independent review panel)",
        "objective response rate (RECIST 1.1)",
        "overall response rate",
        "response rates",
        "complete response (RECIST 1.1, blinded independent central review)",
        "partial response (RECIST 1.1, blinded independent central review)",
        "disease control rate",
        "rate of disease control",
        "time to response"
      ],
      "progression_measures": [
        "time to progression (TTP)",
        "time to progression",
        "duration of response (DoR)",
        "duration of response (RECIST 1.1)",
        "duration of treatment",
        "time to next treatment (TTNT)",
        "time to next treatment"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (general)",
        "adverse events (CTCAE v5.0)",
        "adverse events (grade ≥3; CTCAE v5.0)",
        "adverse events",
        "adverse effects",
        "adverse event rate",
        "significant adverse event rate (grade 3-4)",
        "tolerability",
        "susceptibility",
        "mortality-related toxicity",
        "treatment-related disutility for intravenous administration",
        "diarrhoea",
        "ALT increase",
        "AST increase",
        "neutropenia",
        "fatigue",
        "febrile neutropenia",
        "serious side effects on the skin",
        "pain",
        "ulceration"
      ],
      "serious_events": [
        "serious adverse events (grade ≥3)",
        "serious side effects on the skin"
      ],
      "discontinuations": [
        "treatment discontinuation due to adverse events",
        "dropout rate"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-LC13",
        "EQ-5D-5L",
        "EQ-5D VAS",
        "visual analogue scale (progression-free health state)",
        "BPI-SF",
        "FACT-G GP5",
        "PGI-C",
        "Patient Global Impression of Change (PGIC)",
        "Patient Global Impression of Severity (PGIS)",
        "NSCLC Symptom Assessment Questionnaire (NSCLC SAQ)"
      ],
      "functional_status": [
        "Karnofsky performance status",
        "ECOG performance status"
      ],
      "symptom_measures": [
        "symptomatology (EORTC QLQ-C30)",
        "symptomatology (EORTC QLQ-LC13)",
        "symptomatology (BPI-SF)",
        "symptomatology (FACT-G GP5)",
        "symptomatology (PGI-C)",
        "symptom control",
        "pain",
        "anxiety",
        "physical benefits",
        "psychological benefits",
        "preservation of quality of life",
        "health status (EORTC QLQ-C30)",
        "health status (EORTC QLQ-LC13)",
        "health status (BPI-SF)",
        "health status (FACT-G GP5)",
        "health status (PGI-C)",
        "health-related quality of life (HRQoL)",
        "health-related quality of life",
        "quality of life",
        "health-related quality of life (measured by time to death)"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
        "cost-effectiveness (cost per QALY)"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "utility decrement per cycle of treatment",
        "health-state utilities"
      ],
      "resource_utilization": [
        "treatment-related disutility for intravenous administration"
      ]
    },
    "other": {
      "exploratory_endpoints": [
        "eventless survival",
        "physical benefits",
        "psychological benefits"
      ],
      "biomarkers": []
    }
  }
}